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The aim of our study was to determine whether some bacterial components as well as some proinﬂammatory cytokines can
aﬀect surface mast cell levels. By the use of ﬂow cytometry technique, we documented that freshly isolated mature rat peritoneal
mast cells do express surface TLR2 and TLR4 protein, but not CD14 molecules, and respond to stimulation with TLR2 and
TLR4 ligands by cysteinyl leukotriene generation. The level of TLR2 protein is modulated by PGN and CCL5 treatment, but
not by LPS, LAM, TNF, or IL-6. Surface mast cell TLR4 expression is aﬀected by LPS, LAM, IL-6, and CCL5. Considering that
TLR-mediated activation conditions not only engaged these cells in antibacterial defense and development of inﬂammation but
also might inﬂuence allergic processes, our observations that surface TLR2 and TLR4 expression can be regulated both bacterial
components and proinﬂammatory cytokines seem to be very intriguing and importance.
1.Introduction
Mast cells are found throughout connective tissues of the
body and are particularly prevalent beneath the subepithelial
surface of the skin, in the respiratory system, in the
gastrointestinal and genitourinary tracts, and adjacent to
blood vessels and nerves [1, 2]. Upon activation, these
cells are capable of producing a wide range of media-
tors, including preformed, cytoplasmic granule-associated
mediators, such as histamine, proteases, metalloproteinases
and some cytokines, lipid mediators, including cysteinyl
leukotrienes (cysLTs) and prostaglandins (PGs), and many
de novo synthesized cytokines and chemokines. Mast cell-
derived mediators can exert diverse proinﬂammatory, anti-
inﬂammatory, and/or immunoregulatory eﬀects [3]. That is
whythesecellstakepartnotonlyinmaintaininghomeostasis
[4] but also are important players in inﬂammatory processes
[5, 6] and strongly inﬂuence both innate and adaptive
immuneresponses[3,7,8].Moreover,mastcellsareinvolved
in the development of many pathological processes [9, 10],
inclusively allergic reactions [11, 12]. More and more data
indicate that mast cells play crucial role in host defense,
especially against bacteria, as well [13–15]. Considering
enormous participation of mast cells in various pathophys-
iological processes, it seems to be of great importance to
comprehend mast cell biology as well as to recognize the
factors inﬂuencing mast cell activity.
It is without any doubt that toll-like receptors (TLRs),
a class of pattern recognition molecules, play a crucial
role in early host defense against invading microbes [16].
Several lines of evidence indicate that TLRs are implicated
in inﬂammatory processes, as well [17, 18]. More and more
data suggest the role of TLRs in the development of adaptive
immunity [19]. TLRs are expressed on various types of
immune cells. Diﬀerent TLRs were demonstrated to be
expressed by mast cells (reviewed in [20]), as well; however
the regulation of mast cell TLR expression remain, as yet,
poorly recognized. Taking into account that, on the one
hand, mast cells express TLRs and, on the other hand, that
these cells are signiﬁcantly involved in the development
of both innate and adaptive immunity and host defense
mechanisms in this study, we determined whether some2 Mediators of Inﬂammation
bacterial components, such as lipopolysaccharide (LPS)
from Pseudomonas aeruginosa, lipoarabinomannan (LAM)
from Mycobacterium smegmatis,a n dp e p t y d o g l i c a n( P G N )
from Staphylococcus aureus as well as some proinﬂammatory
cytokines, that is, interleukin (IL)-6, tumor necrosis factor
(TNF), and chemokine CCL5 (RANTES), could inﬂuence
surface TLR2 and TLR4 levels on mast cells.
2.MaterialsandMethods
2.1. Reagents. Dulbecco’s Modiﬁed Eagle’s Medium (DM-
EM), Hanks’ balanced salt solution (HBSS), sodium bicar-
bonate, fetal calf serum (FCS), paraformaldehyde, gentam-
icin, and glutamine were obtained from GIBCO, Life
Technologies (Gaithersburg, Md, USA). Percoll, toluidine
blue, trypan blue, bovine serum albumine (BSA) N-2-
hydroxyethylpiperazine-N -ethanesulphonic acid (HEPES),
NaCl, KCl, MgCl2,C a C l 2, glucose, calcium ionophore
A23187, sodium azide, and LPS from P. aeruginosa were
obtainedfromSigma-AldrichCo.(St.Louis,Mo,USA).PGN
from S. aureus and LAM from M. smegmatis were obtained
from InvivoGen (San Diego, Calif, USA). Nuclear factor
(NF)-κB inhibitor—MG-132 was purchased from Biomol
(Plymouth Meeting, Pa, USA). rr (rat recombinant) CCL-
5, rrIL-6 and rrTNF were obtained from R&D Systems
(Minneapolis, Minn, USA) and CysLT Immunoassay kit was
purchasedfromCaymanChemical(AnnArbor,Mich,USA).
Rabbit anti-rat TLR2 IgG antibodies, rabbit IgG iso-
type control, phycoerythrin (PE)-conjugated donkey anti-
rabbit IgG F(ab )2 fragments, PE-conjugated mouse anti-rat
TLR4 IgG antibodies, and PE-conjugates mouse IgG isotype
control were obtained from Abcam Inc. (Cambridge, Mass,
USA). Goat anti-rat CD14 IgG antibodies, goat IgG isotype
control, ﬂuorescein isothiocyanate (FITC)-conjugated don-
key anti-goat IgG F(ab )2 fragments, goat IgG antibodies
blocking TLR2 and goat IgG antibodies blocking TLR4 were
purchased from Santa Cruz Biotechnology (Santa Cruz,
Calif, USA).
2.2. Mast Cell Isolation. Mast cells were collected from
peritoneal cavities of female albino Wistar rats weighing
200–250g by lavage with 50mL of 1% HBSS supplemented
with 0.015% sodium bicarbonate. After abdominal massage
(90s), the cell suspension was removed from the peritoneal
cavity, centrifuged (150g, 5min, 20◦C), and washed twice in
complete (c) DMEM containing DMEM supplemented with
10%FCS,10μg/mLgentamicin,and2mMglutamine(150g,
5min, 20◦C). To prepare puriﬁed mast cells, the peritoneal
cells were resuspended in 72.5% isotonic Percoll solution
and centrifuged (190g, 15min, 20◦C). Next, isolated mast
cells were washed twice in cDMEM by centrifugation.
P u r i ﬁ e dm a s tc e l l sw e r ec o u n t e da n dr e s u s p e n d e di na n
appropriate volume of cDMEM or medium for rat mast
cells containing 137mMNaCl, 2.7mMKCl, 1mMMgCl2,
1mMCaCl 2, 10mM HEPES buﬀer, 5.6mM glucose, and
1mg/mL BSA (pH of the medium was adjusted to 6.9).
The mast cells were prepared with over 98% purity, as
determined by metachromatic staining with toluidine
blue.
2.3. CysLT Release Assay. Puriﬁed mast cells were resus-
pended in appropriate volume of medium for rat mast cells
to obtain mast cell concentration of 1.5 × 106 cells/mL and
incubated for 60min at 37◦C with LPS at ﬁnal concentration
of 102 ng/mL, LAM or PGN at ﬁnal concentrations of
102μg/mL, calcium ionophore A23187 at ﬁnal concentration
of 5μg/mL (positive control) or buﬀer alone (spontaneous
cysLT generation). The supernatants were collected by
centrifugation (150g, 5min, 20◦C) and analyzed by an
ELISAcommercialkitthatdetectedLTC4 anditsdegradation
products LTD4 and LTE4. The sensitivity of this assay was
<13pg/mL.
To determine the speciﬁcity of bacterial antigen action
on cysLT generation in some experiments, mast cells were
preincubated with anti-TLR2 or anti-TLR4 antibodies (at
ﬁnal concentrations of 20μg/mL), with NF-κB inhibitor
MG-132 (at ﬁnal concentration of 3μM) or medium alone
for15mininahumidiﬁedatmospherewith5%CO2 at37◦C.
The cells were then washed twice, resuspended in medium
and incubated with bacterial antigens, as described above.
2.4. The Eﬀect of Bacterial Components and Cytokines on
TLR2 and TLR4 Expression. Puriﬁed mast cells resuspended
in cDMEM were divided into 90μL aliquots (1.5 × 10cells
each). Subsequently, 10μL of LPS at ﬁnal concentrations of
100 ng/mLand102 ng/mL,PGNandLAMatﬁnalconcentra-
tions of 100 μg/mL and 102 μg/mL, CCL5, IL-6 or TNF (ﬁnal
concentrations of 1pg/mL and 100pg/mL), or cDMEM
(control TLR2 and TLR4 expression on unstimulated mast
cells) was added. Mast cells were incubated for 1,3,6,12,
and 24h at 37◦C in a humidiﬁed incubator with 5% CO2.
After each period of incubation the cells were washed
twice in 1% PBS (150g, 4◦C) and resuspended in 90μLo f
PBS. Additionally, after each period of incubation mast cell
viability was examined by trypan blue exclusion assay.
2.5. Flow Cytometry. For indirect TLR2 and CD14 staining,
m a s tc e l l sw e r eﬁ x e dw i t h1 %p a r a f o r m a l d e h y d ef o r1 5m i n ,
washed twice with 1% PBS (150g, 4◦C), resuspended in
90μLof1%PBSandincubatedwith:(1)rabbitanti-ratTLR2
IgG antibodies or rabbit IgG isotype control and (2) goat
anti-rat CD14 IgG antibodies or goat anti-rat IgG isotype
control, respectively, at ﬁnal concentrations of 1μg/106 mast
cellsat4◦Cfor45min.Afterincubationthecellswerewashed
in 1% PBS (150g, 4◦C) and incubated with PE-conjugated
donkey anti-rabbit IgG F(ab )2 fragments (TLR2 detection)
or FITC-conjugated donkey anti-goat IgG F(ab )2 fragments
(CD14 detection) at ﬁnal concentrations of 1μg/106 mast
c e l l sa t4 ◦C for 45 min in dark. For direct TLR4 staining,
mast cells were suspended in ice cold 1% PBS supplemented
with 1% FCS and 0.05% sodium azide and incubated with
PE-conjugated mouse anti-rat TLR4 IgG antibodies or PE-
conjugatedmouseIgGisotypecontrolatﬁnalconcentrations
of 1μg/106 mast cells at 4◦C for 60min in dark. After incu-
bation with antibodies/isotype control, the cells were washed
twice with 1% PBS (150g, 4◦C) and ﬁnally resuspended
in 300μL of 1% paraformaldehyde. Stained mast cell ﬂuo-
rescence was measured with a FACSCalibur ﬂow cytometer
with CellQuest software. The stimulated mast cell TLR2,Mediators of Inﬂammation 3
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Figure 1: Representative ﬂow cytometry histograms showing (a) TLR2 and (b) TLR4 expression on freshly isolated rat peritoneal mast cells.
Filled histograms: isotype controls and open histograms: TLR expression.
TLR4, and CD14 expression was presented as percentage of
TLR2, TLR4, and CD14 MFI (mean ﬂuorescence intensity)
measured in unstimulated mast cells (referred to as 100%).
2.6. Statistical Analysis. Statistical analysis included mean
value, standard error of the mean (SEM), and Student’s t
test for “small groups”. Values of P<. 05 were considered
statistically signiﬁcant.
3. Results
3.1. Rat Peritoneal Mast Cells Express Functional TLR2 and
TLR4 Molecules. We ﬁrst examined the presence of TLR2,
TLR4, and CD14 proteins on freshly isolated rat peritoneal
mast cells by ﬂow cytometry analysis. We stated that rat
mast cells expressed both TLR2 and TLR4 molecules, and
expression of surface TLR4 was higher than TLR2 level
(Figure 1). We also found that these cells did not express
CD14 protein (data not shown).
We next investigated whether TLR2 ligands, that is, LAM
and PGN, and TLR4 ligand, that is, LPS, would activate rat
mast cells to generation and release cysLTs. We noticed that
stimulation of mast cells with TLR4 agonist LPS for 60min
resulted in synthesis and release of signiﬁcant amounts of
cysLTs, as compared to ionophore A23187-induced cysLT
generation. Mast cell activation with LAM and PGN, the
TLR2 ligands, also caused generation and release of cysLTs;
however the production of cysLTs in response to LAM
was less robust. What is more, we observed that blocking
TLR2 or TLR4 with related antibodies, prior to LAM,
PGN or LPS challenge, strongly and statistically signiﬁcant
(P<. 01) inhibited cysLT generation (Figure 2(a)). We also
documented that preincubation of mast cells with MG-132,
anNF-κBinhibitor,causedastatisticallysigniﬁcant(P<. 01)
decrease in LPS-, LAM-, and PGN-induced cysLT release
(Figure 2(b)).
3.2. Bacterial Components and Cytokines Can Modulate TLR2
Expression on Mast Cells. In order to examine the inﬂuence
of LPS, LAM, and PGN as well as IL-6, TNF and CCL5
on surface TLR2 expression mast cells were incubated with
each stimulant (or with cDMEM) for 1,3,6,12, or 24h
and TLR2 level was estimated by ﬂow cytometry analysis.
We found that stimulation of mast cells with LPS used at
concentrations of 100 ng/mL and 102 ng/mL or LAM used at
concentrations of 1μg/mL and 102μg/mL for 1,3,6,12, and
24hdidnotaﬀectthelevelofTLR2protein(Figures3(a)and
3(b)). Treatment of mast cells with 1μg/mL of PGN caused
statistically signiﬁcant (P<. 01) increase in TLR2 expression
level following 1 and 3h incubation, as compared with the
control unstimulated cells (Figures 3(c), 3(d), and 3(e)).
We also established that mast cell TLR2 expression was not
modulatedbyTNForIL-6treatment(Figures4(a)and4(b));
however, chemokine CCL5 at concentrations of 100 pg/mL
and 102 pg/mL signiﬁcantly (P<. 01) downregulated the
expression of TLR2 after 24h incubation (Figures 4(c), 4(d),
and 4(e)).
3.3. Bacterial Components and Cytokines Can Modulate TLR4
Expression on Mast Cells. We also studied the changes of
TLR4 expression by mast cell treatment with LPS, LAM, and
PGN. LPS at concentration of 1ng/mL caused signiﬁcant
(P<. 01) downregulation of TLR4 level following 3h
incubation, while the exposure of mast cells to 102 ng/mL of
LPS resulted in a statistically signiﬁcant (P<. 01) increased
expression of TLR4 after prolonged 12 and 24h incubation4 Mediators of Inﬂammation
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Figure 2: The eﬀect of LPS, LAM and PGN on rat mast cell
cysLT synthesis. (a) Mast cells were preincubated with cDMEM
(control) or anti-TLR antibodies for 15min and after washing
incubatedwithLPS,LAM,PGNorbuﬀeralone(spontaneouscysLT
generation) for 60 min. Results are expressed as the mean±SEM
of three independent experiments and each experiment was done
in duplicate (n = 6). (b) Mast cells were preincubated with
cDMEM (control) or MG-132 for 15min and after washing
incubatedwithLPS,LAM,PGNorbuﬀeralone(spontaneouscysLT
generation) for 60 min. Results are expressed as the mean±SEM of
three independent experiments and each experiment was done in
duplicate (n = 6). ∗∗P<. 01.
(Figures 5(a), 5(d), 5(e), and 5(f)). Mast cell treatment with
102μg/mL LAM upregulated TLR4 expression following 1h
incubation (Figures 5(b) and 5(g)). PGN-treatment aﬀected
mast cell TLR4 expression, especially following 1,3 and
6h stimulation; however, the observed variations were not
statistically signiﬁcant (Figure 5(c)).
The exposure of mast cells to TNF did not cause essential
alteration in surface TLR4 level, at any time point examined,
as shown in Figure 6(a). Treatment of mast cells with
1pg/mL of IL-6 caused statistically signiﬁcant (P<. 01)
increase in TLR4 expression level following 3h incubation,
as compared with the control unstimulated cells (Figures
6(b) and 6(d)), while stimulation of mast cells with 1pg/mL
CCL5 induced signiﬁcant decrease in TLR4 level following
prolonged 12h incubation (Figures 6(c) and 6(e)).
4. Discussion
It is well documented that mast cells express mRNA for
TLR2andTLR4proteins. TLR2andTLR4mRNAexpression
w a sd e t e c t e di nb o t hi m m a t u r em u r i n e[ 21–25]a n dh u m a n
[26–30] mast cells. The gene transcripts of TLR2 and TLR4
molecules were also found in mature murine [22]a n d
human [26, 31] mast cells. Mast cell surface expression of
TLR2 and TLR4 proteins has been sparsely estimated. TLR2
at the protein level was found on immature human [26–
28, 30] mast cells as well as on mature mouse mast cells
isolated from peritoneal cavity [24] and intestine [32], and
mature nasal polyp human mast cells [33]. TLR4 protein was
detected on immature human [27, 29, 30]a n dm o u s e[ 22]
mast cells as well as on mature murine mast cells isolated
from peritoneal cavity and skin [22]. To our knowledge, this
studyistheﬁrstreportdocumentingTLR2andTLR4protein
expression by mature freshly isolated rat peritoneal mast
cells. It should be stressed that we stated that TLR4 level is
higher than TLR2 expression. Moreover, we established that
mast cells respond to stimulation with both PGN and LAM,
that is, TLR2 ligands, as well as to LPS, that is, TLR4 ligand,
by generation and release of cysLTs, according to previous
reports [33–35], and this eﬀect is partially, but signiﬁcantly,
decreased by anti-TLR2 or anti-TLR4 antibodies. What is
more, by the use of ﬂow cytometry technique, we also
stated that rat peritoneal mast cells do not express CD14
molecules. Previously, McCurdy et al. [23] and Stassen et al.
[36] demonstrated lack of CD14 protein expression on the
surfaceofmurinebonemarrow-derivedmastcells(BMMCs)
and Varadaradjalou et al. [29] did not notice surface CD14
molecules on cord blood-derived mast cells (CBMCs).
Considering the signiﬁcance of TLR molecules in the
development of both innate and adaptive immunity [37, 38]
it seems to be of great importance to comprehend factors
that inﬂuence TLR expression. It was indicated that some
cytokines, including proinﬂammatory cytokines, can mod-
ulate the expression of TLR2 and/or TLR4 on macrophages
[39], monocytes [40], endothelial cells [41], neutrophils
[42], and epithelial cells [43]. Several reports described
the eﬀect of bacterial components on TLR expression, as
well. It was shown that LPS upregulates the level of mRNA
for TLR2, TLR4, and TLR9 in human monocytes and
macrophages [44, 45] but decreases TLR4 mRNA expression
in murine macrophages [46]. It was also documented that
LPS stimulates increase in TLR2 and TLR4 expression on
human airway epithelial cells [47] and elevation of mRNA
for TLR4 in endothelial cells [41]. Hussain et al. [48]
observed PGN-induced upregulation of TLR2 expressionMediators of Inﬂammation 5
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Figure 3: The eﬀect of (a) LPS, (b) LAM, and (c) PGN on TLR2 expression on rat mast cells. Mast cells were incubated with bacterial
components or cDMEM (control TLR2 expression on unstimulated cells referred to as 100%) for 1,3,6,12, or 24 hours. LPS concentrations
−1ng/mL(darkbars)and102 ng/mL(brightbars)LAMandPGNconcentrations −1μg/mL(darkbars)and102 μg/mL(brightbars).Results
are presented as a percentage of control TLR2 expression. Each point represents the mean±SEM of 6 independent experiments. ∗∗P<. 01.
(d)RepresentativeﬂowcytometryhistogramshowingTLR2expressiononratmastcellstreatedwith1μg/mLPGNfor1h.(e)Representative
ﬂow cytometry histogram showing TLR2 expression on rat mast cells treated with 1μg/mL PGN for 3h. Filled histograms: untreated mast
cells (control) and open histograms: PGN-treated mast cells.
in murine pleural mesothelial cells, and Muzio et al. [45]
documented LAM-induced increase in mRNA for TLR4 in
human leukocytes.
The impact of humoral factorsand bacterial components
on mast cell TLR expression is, as yet, not well recognized.
Therefore, we decided to determine the inﬂuence of some
important bacterial antigens, such as PGN—a main cell wall
component of Gram-positive bacteria, LPS—an important
component of Gram-negative bacteria, and LAM—a major
virulence factor in the bacteria genus Mycobacterium, that is,6 Mediators of Inﬂammation
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Figure 4: The eﬀect of (a) TNF, (b) IL-6, and (c) CCL5 on TLR2 expression on rat mast cells. Mast cells were incubated with cytokines
or cDMEM (control TLR2 expression on unstimulated cells referred to as 100%) for 1,3,6,12, or 24 hours. Cytokine concentrations
−1pg/mL (dark bars) and 102 pg/mL (bright bars). Results are presented as a percentage of control TLR2 expression. Each point represents
the mean±SEM of 6 independent experiments. ∗∗P<. 01. (d) Representative ﬂow cytometry histogram showing TLR2 expression on rat
mast cells treated with 1pg/mL CCL5 for 24h. (e) Representative ﬂow cytometry histogram showing TLR2 expression on rat mast cells
treated with 102 pg/mL CCL5 for 24h. Filled histograms: untreated mast cells (control) and open histograms: CCL5-treated mast cells.
TLR2 and TLR4 ligands, respectively, on TLR2 and TLR4
expression on mast cells. Taking into account that mast cells
play a crucial role in inﬂammatory processes [5, 6], we also
examined the eﬀect of some proinﬂammatory cytokines,
such as IL-6, TNF, and chemokine CCL5 on mast cell
TLR2 and TLR4 levels. We observed that LPS mast cell
treatment has no eﬀect on the expression of TLR2 at any
time point examined whereas it decreases TLR4 expression
following 3h incubation and increases TLR4 protein level
following 12 and 24h incubation. PGN treatment causes
upregulation of TLR2 expression after 1 and 3h incubation
and LAM-treatment does not aﬀect TLR2 expression butMediators of Inﬂammation 7
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Figure 5: The eﬀect of (a) LPS, (b) LAM, and (c) PGN on TLR4 expression on rat mast cells. Mast cells were incubated with bacterial
components or cDMEM (control TLR4 expression on unstimulated cells referred to as 100%) for 1,3,6,12, or 24 hours. LPS concentrations
−1ng/mL (dark bars) and 102 ng/mL (bright bars) and LAM and PGN concentrations −1μg/mL (dark bars) and 102 μg/mL (bright bars).
Results are presented as a percentage of control TLR4 expression. Each point represents the mean±SEM of 6 independent experiments.
∗∗P<. 01. (d) Representative ﬂow cytometry histogram showing TLR4 expression on rat mast cells treated with 1ng/mL LPS for 3h. (e)
Representative ﬂow cytometry histogram showing TLR4 expression on rat mast cells treated with 102 ng/mL LPS for 12h. (f) Representative
ﬂow cytometry histogram showing TLR4 expression on rat mast cells treated with 102 ng/mL LPS for 24h. (g) Representative ﬂow cytometry
histogram showing TLR4 expression on rat mast cells treated with 102 μg/mL LAM for 1h. Filled histograms: untreated mast cells (control)
and open histograms: LPS- or LAM-treated mast cells.8 Mediators of Inﬂammation
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Figure 6: The eﬀect of (a) TNF, (b) IL-6, and (c) CCL5 on TLR4 expression on rat mast cells. Mast cells were incubated with cytokines
or cDMEM (control TLR4 expression on unstimulated cells referred to as 100%) for 1,3,6, 12, or 24 hours. Cytokine concentrations
−1pg/mL (dark bars) and 102 pg/mL (bright bars). Results are presented as a percentage of control TLR2 expression. Each point represents
the mean±SEM of 6 independent experiments. ∗∗P<. 01. (d) Representative ﬂow cytometry histogram showing TLR4 expression on rat
mast cells treated with 1pg/mL IL-6 for 3h. (e) Representative ﬂow cytometry histogram showing TLR4 expression on rat mast cells treated
with 1pg/mL CCL5 for 14h. Filled histograms: untreated mast cells (control) and open histograms: IL-6- or CCL5-treated mast cells.
causes signiﬁcant increase in TLR4 expression following
1h incubation. So far, only Kubo et al. [27] examined
the eﬀect of bacterial components on TLR4 expression on
mast cells. These authors stated that both LPS and LTA,
but not PGN, stimulate augmentation of TLR4 mRNA in
human mast cell lines LAD2 and HMC-1; however, only LPS
induces an increase in TLR4 protein expression following
24h incubation. It was also established that poly (I:C), a
synthetic dsRNA construct, enhances TLR3 level in human
and murine mast cells [31, 49]. We also documented that out
of cytokines TNF does not modulate either TLR2 or TLR4
protein levels while IL-6 treatment of mast cells induces
an increase in TLR4 expression following 3h incubation.
The exposure of mast cells to CCL5 resulted in decreasedMediators of Inﬂammation 9
expression of both TLR2, following 24h incubation, and
TLR4 level, following 12 and 24h incubation. Previously,
Okumura et al. [50] found that TLR4 expression on
human peripheral blood-derived mast cells is upregulated
by interferon (IFN)-γ, and Yang et al. [51] stated that IL-
12 induces signiﬁcant increase in expression of TLR2 and
TLR4 in P815 mast cell line. There was also documented that
granulocyte-macrophage colony stimulating factor (GM-
SCF) modulates expression of TLR3 and TLR7 in P815
cells [52] and cathelicidin LL-37 increases the level of TLR4
mRNA and TLR4 protein in mast cell line LAD2 [53].
The changes in TLR2 and TLR4 level on mast cells
induced by bacterial components may be caused by a
direct eﬀect of ligands, that is, PGN or LPS, on its own
receptors TLR2 and TLR4, respectively. However, observed
modiﬁcation of TLR expression could be mediated by an
indirect mechanism involving cytokine production. It has
been established that prolonged mast cell stimulation with
b a c t e r i a lc e l lw a l lc o m p o n e n t s ,s u c ha sL P Sa n dP G N ,
resulted in de novo synthesis and release various cytokines
[23, 25, 54, 55]. Thus, the increased expression of TLR4
following 12 and 24h LPS stimulation could be resulted
from cytokine activity. Unfortunately, we could not explain
the exact mechanism of the IL-6 upregulation of TLR4 level
and CCL5 downregulation of TLR2 and TLR4 expression.
Considering that TLR-mediated activation of mast cells
conditions not only engaged these cells in antibacterial
defense and development of inﬂammation but also might
inﬂuence allergic processes [56, 57], our observations that
mastcellsurfaceTLR2andTLR4expressioncanberegulated
by both bacterial cell wall components and proinﬂammatory
cytokinesseemtobeveryintriguing.However,furtherexper-
iments are needed to clarify the mechanisms of modulation
mast cell TLR2 and TLR4 expression by these factors.
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